In this roundtable, perspectives on open access publishing, its importance, and ways of working that should be adopted post-pandemic will be shared. With only three pharma companies mandating that their research is published open access, we discuss why this number is so low and discuss experiences from the companies that have taken this step. From a publisher standpoint, one key barrier to open access has been finding a sustainable publishing model. With increasing numbers of Read & Publish deals and transformative agreements, we explore what approaches could be considered and suggest ways in which we can work towards sustainable open access.
Discussion objectives:
- Discuss the key benefits of publishing open access
- Understand key stakeholder perspectives and barriers to publishing open access
- Learn how barriers to open access may be overcome to achieve a more open future
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.